nach oben

Current Hepatology Reports

Erschienen in:

18.01.2024

Prophylaxis and Treatment of Bacterial Infections in Cirrhosis

verfasst von: Lauren Gilbert, Zachary Fricker

Erschienen in: Current Hepatology Reports | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We aim to succinctly summarize key clinical management principles in commonly encountered clinical scenarios with regard to prevention, diagnosis, and management of bacterial infections in patients with cirrhosis.

Recent Findings

We review studies detailing the role for antibiotic prophylaxis in acute liver failure and in alcohol-related hepatitis. We also review growing concerns related to antibiotic resistance and emerging biomarkers for infection prediction in cirrhosis.

Summary

We found that there is evidence of improved outcomes with administration of antibiotic prophylaxis to cirrhotic patients in specific clinical situations (such as acute gastrointestinal hemorrhage, low ascitic total fluid protein), while evidence of benefit is lacking in other circumstances (acute liver failure, alcoholic hepatitis). Additionally, there are several biomarkers that have shown promise in predicting infection in cirrhosis, which may help us tailor antibiotic exposure and mitigate growing antibiotic resistance.

Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol. 2022;19(2):112–34. https://doi.org/10.1038/s41575-021-00520-7.CrossRefPubMed

Campillo B, Pernet P, Bories PN, Richardet JP, Devanlay M, Aussel C. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol. 1999;11(7):755–9. https://doi.org/10.1097/00042737-199907000-00013.CrossRefPubMed

Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, Boccia S, Colloredo-Mels G, Corigliano P, Fornaciari G, Marenco G, Pistarà R, Salvagnini M, Sangiovanni A. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001;33(1):41–8. https://doi.org/10.1016/s1590-8658(01)80134-1.CrossRefPubMed

Bajaj JS, O'Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, Brown G, Noble NA, Thacker LR, Kamath PS, NACSELD. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012;56(6):2328–35. https://doi.org/10.1002/hep.25947.CrossRefPubMed

Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, Burroughs AK. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010 Oct;139(4):1246–56. https://doi.org/10.1053/j.gastro.2010.06.019.CrossRefPubMed

Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014. https://doi.org/10.1002/hep.31884.CrossRefPubMed

Wong CL, Holroyd-Leduc J, Thorpe KE, Straus SE. Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results? JAMA. 2008;299(10):1166–78. https://doi.org/10.1001/jama.299.10.1166.CrossRefPubMed

Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol. 2000;32(1):142–53. https://doi.org/10.1016/S0168-8278(00)80201-9.CrossRefPubMed

Runyon BA, Hoefs JC. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. Hepatology. 1984;4(6):1209–11. https://doi.org/10.1002/hep.1840040619.CrossRefPubMed

10.

Llach J, Rimola A, Navasa M, Ginès P, Salmerón JM, Ginès A, Arroyo V, Rodés J. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology. 1992;16(3):724–7. https://doi.org/10.1002/hep.1840160318.CrossRefPubMed

11.

Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology. 1988;95(5):1351–5. https://doi.org/10.1016/0016-5085(88)90372-1.CrossRefPubMed

12.

Akriviadis EA, Runyon BA. Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology. 1990;98(1):127–33. https://doi.org/10.1016/0016-5085(90)91300-u.CrossRefPubMed

13.

Runyon BA. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. Hepatology. 1990;12(4 Pt 1):710–5. https://doi.org/10.1002/hep.1840120415.CrossRefPubMed

14.

Pelletier G, Lesur G, Ink O, Hagege H, Attali P, Buffet C, Etienne JP. Asymptomatic bacterascites: is it spontaneous bacterial peritonitis? Hepatology. 1991;14(1):112–5. https://doi.org/10.1002/hep.1840140118.CrossRefPubMed

15.

Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, Krag A, Laleman W, Gines P. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60. https://doi.org/10.1016/j.jhep.2018.03.024.CrossRef

16.

Deutsch-Link S, Campbell PT, Shah ND. PRO: Ascitic fluid cell count should be routinely sent with every therapeutic paracentesis to assess for spontaneous bacterial peritonitis. Clin Liver Dis (Hoboken). 2023;22(4):140–2. https://doi.org/10.1097/CLD.0000000000000084.CrossRefPubMedPubMedCentral

17.

Evans LT, Kim WR, Poterucha JJ, Kamath PS. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology. 2003;37(4):897–901. https://doi.org/10.1053/jhep.2003.50119.CrossRefPubMed

18.

Cadranel JF, Nousbaum JB, Bessaguet C, Nahon P, Nguyen-Khac E, Moreau R, Thévenot T, Silvain C, Bureau C, Nouel O, Pilette C, Paupard T, Pauwels A, Sapey T, Grangé JD, Tran A. Low incidence of spontaneous bacterial peritonitis in asymptomatic cirrhotic outpatients. World J Hepatol. 2013;5(3):104–8. https://doi.org/10.4254/wjh.v5.i3.104.CrossRefPubMedPubMedCentral

19.

Arzivian A, Duong T. The incidence of spontaneous bacterial peritonitis in patients with cirrhosis-related ascites undergoing elective outpatient large-volume paracentesis. Cureus. 2023;15(12):e50191. https://doi.org/10.7759/cureus.50191.CrossRefPubMedPubMedCentral

20.

Kim JJ, Tsukamoto MM, Mathur AK, Ghomri YM, Hou LA, Sheibani S, Runyon BA. Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol. 2014;109(9):1436–42. https://doi.org/10.1038/ajg.2014.212.CrossRefPubMed

21.

Garcia-Tsao G, Members of the Veterans Affairs Hepatitis C Resource Center Program, Lim J. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104(7):1802–29. https://doi.org/10.1038/ajg.2009.191.CrossRefPubMed

22.

Fernández J, Prado V, Trebicka J, Amoros A, Gustot T, Wiest R, Deulofeu C, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol. 2019;70(3):398–411. https://doi.org/10.1016/j.jhep.2018.11.015.CrossRefPubMed

23.

Fernández J, Bert F, Nicolas-Chanoine MH. The challenges of multi-drug-resistance in hepatology. J Hepatol. 2016;65(5):1043–54. https://doi.org/10.1016/j.jhep.2016.08.006.CrossRefPubMed

24.

Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403–9. https://doi.org/10.1056/NEJM199908053410603.CrossRefPubMed

25.

Alhumaid S, Al Mutair A, Al Alawi Z, Zaidi ARZZ, Rabaan AA, Elhazmi A, Al-Omari A. Proton pump inhibitors use and risk of developing spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Gut Pathogens. 2021;13(1):17. https://doi.org/10.1186/s13099-021-00414-8.CrossRefPubMedPubMedCentral

26.

Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol. 2012;10(4):422–7. https://doi.org/10.1016/j.cgh.2011.11.019.CrossRefPubMed

27.

Bajaj JS, Ananthakrishnan AN, Hafeezullah M, Zadvornova Y, Dye A, McGinley EL, Saeian K, Heuman D, Sanyal AJ, Hoffmann RG. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol. 2010 Jan;105(1):106–13. https://doi.org/10.1038/ajg.2009.615.CrossRefPubMed

28.

O'Leary JG, Reddy KR, Wong F, Kamath PS, Patton HM, Biggins SW, Fallon MB, Garcia-Tsao G, Subramanian RM, Malik R, Thacker LR, Bajaj JS. North American Consortium for the Study of End-Stage Liver Disease. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(4):753–9.e1-2. https://doi.org/10.1016/j.cgh.2014.07.060.CrossRefPubMed

29.

Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, Rolston DDK, Sferra TJ, Hernandez AV. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28(2):235–42. https://doi.org/10.1111/jgh.12065.CrossRefPubMed

30.

Hernández-Gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X, Miñana J, Guarner C, Villanueva C. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol. 2012;107(3):418–27. https://doi.org/10.1038/ajg.2011.456.CrossRefPubMed

31.

Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H, Vienna Hepatic Hemodynamic Lab. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58(5):911–21. https://doi.org/10.1016/j.jhep.2012.12.011.CrossRefPubMed

32.

Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, Hagmann M, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146(7):1680–1690.e1. https://doi.org/10.1053/j.gastro.2014.03.005.CrossRefPubMed

33.

Fong TL, Akriviadis EA, Runyon BA, Reynolds TB. Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology. 1989;9(3):423–6. https://doi.org/10.1002/hep.1840090313.CrossRefPubMed

34.

Saffo S, To UK, Santoiemma PP, Laurito M, Haque L, Rabiee A, Verna EC, Angarone MP, Garcia-Tsao G. Changes in ascitic fluid polymorphonuclear cell count after antibiotics are associated with mortality in spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol. 2022;20(5):e1201–4. https://doi.org/10.1016/j.cgh.2021.07.019.CrossRefPubMed

35.

Astaldi G, Strosselli E. Peroral biopsy of the intestinal mucosa in hepatic cirrhosis. Am J Dig Dis. 1960;5:603–12. https://doi.org/10.1007/BF02290193.CrossRefPubMed

36.

Pascual S, Such J, Esteban A, Zapater P, Casellas JA, Aparicio JR, Girona E, Gutiérrez A, Carnices F, Palazón JM, Sola-Vera J, Pérez-Mateo M. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology. 2003;50(53):1482–6.PubMed

37.

Ersöz G, Aydin A, Erdem S, Yüksel D, Akarca U, Kumanlioglu K. Intestinal permeability in liver cirrhosis. Eur J Gastroenterol Hepatol. 1999;11(4):409–12. https://doi.org/10.1097/00042737-199904000-00009.CrossRefPubMed

38.

Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J, Soares EC, Kim DJ, Kim SE, Marino M, Vorobioff J, Barea RCR, Merli M, Elkrief L, Vargas V, Krag A, Singh SP, Lesmana LA, Toledo C, et al. International Club of Ascites Global Study Group. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology. 2019;156(5):1368–1380.e10. https://doi.org/10.1053/j.gastro.2018.12.005.CrossRefPubMed

39.

Runyon BA, Morrissey RL, Hoefs JC, Wyle FA. Opsonic activity of human ascitic fluid: a potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology. 1985;5(4):634–7. https://doi.org/10.1002/hep.1840050419.CrossRefPubMed

40.

Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133(3):818–24. https://doi.org/10.1053/j.gastro.2007.06.065.CrossRefPubMed

41.

Loomba R, Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol. 2009;7(4):487–93. https://doi.org/10.1016/j.cgh.2008.12.018.CrossRefPubMed

42.

Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, Landeira C, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol. 2008;48(5):774–9. https://doi.org/10.1016/j.jhep.2008.01.024.CrossRefPubMed

43.

Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology. 1986;91(6):1343–6. https://doi.org/10.1016/0016-5085(86)90185-x.CrossRefPubMed

44••.

Moreau R, Elkrief L, Bureau C, Perarnau JM, Thévenot T, Saliba F, Louvet A, Nahon P, Lannes A, Anty R, Hillaire S, Pasquet B, Ozenne V, Rudler M, Ollivier-Hourmand I, Robic MA, d'Alteroche L, Di Martino V, Ripault MP, et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology. 2018 Dec;155(6):1816–1827.e9. https://doi.org/10.1053/j.gastro.2018.08.026. Findings from this study suggest that primary prophylaxis for spontaneous bacterial peritonitis in Child-Pugh class C patients may only benefit those with low total ascites protein (<15 g/L).

45.

Ginès P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forne M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12(4):716–24. https://doi.org/10.1002/hep.1840120416.CrossRefPubMed

46.

Ginés P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, Miranda ML, Llach J, Salmerón JM, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12(4 Pt 1):716–24. https://doi.org/10.1002/hep.1840120416.CrossRefPubMed

47.

Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med. 1995;122(8):595–8. https://doi.org/10.7326/0003-4819-122-8-199504150-00007.CrossRefPubMed

48.

Lontos S, Shelton E, Angus PW, Vaughan R, Roberts SK, Gordon A, Gow PJ. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis. 2014;15(5):260–7. https://doi.org/10.1111/1751-2980.12132.CrossRefPubMed

49.

Salehi S, Tranah TH, Lim S, Heaton N, Heneghan M, Aluvihare V, Patel VC, Shawcross DL. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. Aliment Pharmacol Ther. 2019;50(4):435–41. https://doi.org/10.1111/apt.15326.CrossRefPubMedPubMedCentral

50.

Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, Fratte S, Bohn B, Kitmacher P, Stahl JP, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology. 1995;22(4 Pt 1):1171–4. https://doi.org/10.1016/0270-9139(95)90626-6.CrossRefPubMed

51.

Yim HJ, Suh SJ, Jung YK, Yim SY, Seo YS, Lee YR, Park SY, Jang JY, Kim YS, Kim HS, Kim BI, Um SH. Daily norfloxacin vs. weekly ciprofloxacin to prevent spontaneous bacterial peritonitis: a randomized controlled trial. Am J Gastroenterol. 2018;113(8):1167–76. https://doi.org/10.1038/s41395-018-0168-7.CrossRefPubMed

52.

Terg R, Llano K, Cobas SM, Brotto C, Barrios A, Levi D, Wasen W, Bartellini MA. Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages. J Hepatol. 1998;29(3):437–42. https://doi.org/10.1016/s0168-8278(98)80062-7.CrossRefPubMed

53.

Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut. 2012;61(2):297–310. https://doi.org/10.1136/gutjnl-2011-300779. Epub 2011 Dec 6. Erratum in: Gut. 2012 Apr;61(4):636CrossRefPubMed

54.

Boivin Z, Perez MF, Atuegwu NC, Anzueto A, Mortensen EM. Impact of cirrhosis on pneumonia-related outcomes in hospitalized older veterans. Am J Med Sci. 2019;357(4):296–301. https://doi.org/10.1016/j.amjms.2019.01.004.CrossRefPubMedPubMedCentral

55.

Reuken PA, Stallmach A, Bruns T. Mortality after urinary tract infections in patients with advanced cirrhosis - relevance of acute kidney injury and comorbidities. Liver Int. 2013;33(2):220–30. https://doi.org/10.1111/liv.12029.CrossRefPubMed

56.

Bartoletti M, Giannella M, Lewis RE, Viale P. Bloodstream infections in patients with liver cirrhosis. Virulence. 2016;7(3):309–19. https://doi.org/10.1080/21505594.2016.1141162.CrossRefPubMedPubMedCentral

57•.

Kutmutia R, Tittanegro T, China L, Forrest E, Kallis Y, Ryder SD, Wright G, Freemantle N, O'Brien A. Evaluating the role of antibiotics in patients admitted to hospital with decompensated cirrhosis: lessons from the ATTIRE trial. Am J Gastroenterol. 2023 Jan;118(1):105–13. https://doi.org/10.14309/ajg.0000000000001937. This post hoc analysis of data from the ATTIRE trial showed no reduction in hospital-acquired infections with routine antibiotic prophylaxis in patients with cirrhosis.

58.

Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29(6):1655–61. https://doi.org/10.1002/hep.510290608.CrossRefPubMed

59.

Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, Uribe M. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther. 2011;34(5):509–18. https://doi.org/10.1111/j.1365-2036.2011.04746.x.CrossRefPubMed

60.

Fernández J. Ruiz del Arbol L, Gómez C, Durandez R, Serradilla R, Guarner C, Planas R, Arroyo V, Navasa M. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006;131(4):1049–56; quiz 1285. https://doi.org/10.1053/j.gastro.2006.07.010.CrossRefPubMed

61•.

Louvet A, Labreuche J, Dao T, Thévenot T, Oberti F, Bureau C, Paupard T, Nguyen-Khac E, Minello A, Bernard-Chabert B, Anty R, Wartel F, Carbonell N, Pageaux GP, Hilleret MN, Moirand R, Nahon P, Potey C, Duhamel A, Mathurin P. Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial. JAMA. 2023;329(18):1558–66. https://doi.org/10.1001/jama.2023.4902. Findings from this study suggest that routine antibiotic prophylaxis in patients with alcohol-related hepatitis decreases incidence of infection but does not improve other outcomes, including 60-day mortality, incidence of hepatorenal syndrome, proportion with pre-specified MELD decrease, or proportion with favorable Lille score.

62.

Karvellas CJ, Cavazos J, Battenhouse H, Durkalski V, Balko J, Sanders C, Lee WM. US Acute Liver Failure Study Group. Effects of antimicrobial prophylaxis and bloodstream infections in patients with acute liver failure: a retrospective cohort study. Clin Gastroenterol Hepatol. 2014;12(11):1942–9.e1. https://doi.org/10.1016/j.cgh.2014.03.011.CrossRefPubMedPubMedCentral

63.

Shingina A, Mukhtar N, Wakim-Fleming J, Alqahtani S, Wong RJ, Limketkai BN, Larson AM, Grant L. Acute liver failure guidelines. Am J Gastroenterol. 2023;118(7):1128–53. https://doi.org/10.14309/ajg.0000000000002340.CrossRefPubMed

64.

Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. https://doi.org/10.1016/S0140-6736(21)02724-0.CrossRef

65.

Badal BD, Silvey S, Dragilev L, O’Leary JG, Morgan TR, Cheung R, Patel A, et al. Primary prophylaxis for spontaneous bacterial peritonitis is linked to antibiotic resistance in the Veterans Health Administration. Hepatology. 2023;77(6):2030–40. https://doi.org/10.1097/HEP.0000000000000184.CrossRefPubMed

66.

Merli M, Lucidi C, Di Gregorio V, Falcone M, Giannelli V, Lattanzi B, Giusto M, Ceccarelli G, Farcomeni A, Riggio O, Venditti M. The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey. PLoS One. 2015;10(5):e0127448. https://doi.org/10.1371/journal.pone.0127448.CrossRefPubMedPubMedCentral

67.

Ardolino E, Wang SS, Patwardhan VR. Evidence of significant ceftriaxone and quinolone resistance in cirrhotics with spontaneous bacterial peritonitis. Dig Dis Sci. 2019;64(8):2359–67. https://doi.org/10.1007/s10620-019-05519-4.CrossRefPubMed

68.

Fernández J, Piano S, Bartoletti M, Wey EQ. Management of bacterial and fungal infections in cirrhosis: the MDRO challenge. J Hepatol. 2021;75(Suppl 1):S101–17. https://doi.org/10.1016/j.jhep.2020.11.010.CrossRefPubMed

69.

Su DH, Zhuo C, Liao K, Cheng WB, Cheng H, Zhao XF. Value of serum procalcitonin levels in predicting spontaneous bacterial peritonitis. Hepatogastroenterology. 2013;60(124):641–6. https://doi.org/10.5754/hge12645.CrossRefPubMed

70.

Lazzarotto C, Ronsoni MF, Fayad L, Nogueira CL, Bazzo ML, Narciso-Schiavon JL, de Lucca SL, Dantas-Corrêa EB. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann Hepatol. 2013;12(4):599–607.CrossRefPubMed

71.

Lin KH, Wang FL, Wu MS, Jiang BY, Kao WL, Chao HY, Wu JY, Lee CC. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis. Diagn Microbiol Infect Dis. 2014;80(1):72–8. https://doi.org/10.1016/j.diagmicrobio.2014.03.029.CrossRefPubMed

72.

Sundaram V, Kaung A, Rajaram A, Lu SC, Tran TT, Nissen NN, Klein AS, Jalan R, Charlton MR, Jeon CY. Obesity is independently associated with infection in hospitalized patients with end-stage liver disease. Aliment Pharmacol Ther. 2015;42(11-12):1271–80. https://doi.org/10.1111/apt.13426.CrossRefPubMed

73.

Tsiakalos A, Karatzaferis A, Ziakas P, Hatzis G. Acute-phase proteins as indicators of bacterial infection in patients with cirrhosis. Liver Int. 2009;29(10):1538–42. https://doi.org/10.1111/j.1478-3231.2009.02088.x.CrossRefPubMed

74.

Albillos A, de-la Hera A Alvarez-Mon M. Serum lipopolysaccharide-binding przotein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet. 2004 363(9421):1608-1610. doi: https://doi.org/10.1016/S0140-6736(04)16206-5.

75.

Kadam N, Acharya S, Shukla S, Gupta K. Ascitic fluid high sensitive C-reactive protein (hs-CRP). A prognostic marker in cirrhosis with spontaneous bacterial peritonitis. J Clin Diagn Res. 2016 Apr;10(4):OC20–4. https://doi.org/10.7860/JCDR/2016/17931.7610.CrossRefPubMedPubMedCentral

Titel: Prophylaxis and Treatment of Bacterial Infections in Cirrhosis
verfasst von: Lauren Gilbert
Zachary Fricker
Publikationsdatum: 18.01.2024
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 1/2024
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-024-00633-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Addiction and Liver Disease: Exploring the Complex Relationship and Implications for Clinical Management

Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon

Systemic Disease and Portal Hypertension

Hepatic Sarcoidosis: A Review of the Diagnosis and Management

Portal Vein Thrombosis in Patients with Cirrhosis